Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 32 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 7608693

    High affinity human antibodies to human IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 27, 2009 · Expires Oct 22, 2029

    granted
  2. US 7605237

    High affinity human antibodies to human IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 20, 2009 · Expires Oct 15, 2029

    granted
  3. US 7582298

    High affinity antibodies to human IL-6 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 1, 2009 · Expires Aug 27, 2029

    granted
  4. US 7576065

    Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 18, 2009 · Expires Aug 13, 2029

    granted
  5. US 7572893

    IL-1 antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 11, 2009 · Expires Aug 6, 2029

    granted
  6. US 7557084

    IL-18 specific polypeptides and therapeutic uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 7, 2009 · Expires Jul 2, 2029

    granted
  7. US 7534868

    Human antibodies to human delta like ligand 4

    REGENERON PHARMACEUTICALS, INC. · Granted May 19, 2009 · Expires May 14, 2029

    granted
  8. US 7534604

    Fusion polypeptides capable of activating receptors

    REGENERON PHARMACEUTICALS, INC. · Granted May 19, 2009 · Expires May 14, 2029

    granted
  9. US 7531172

    Methods of treating diseases with a VEGF antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted May 12, 2009 · Expires May 7, 2029

    granted
  10. US 7531173

    Ophthalmic composition of a VEGF antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted May 12, 2009 · Expires May 7, 2029

    granted
  11. US 7524499

    Modified chimeric polypeptides with improved pharmacokinetic properties

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 28, 2009 · Expires Apr 23, 2029

    granted
  12. US 7521211

    IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 21, 2009 · Expires Apr 16, 2029

    granted
  13. US 7521049

    Use of VEGF inhibitors for treatment of eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 21, 2009 · Expires Apr 16, 2029

    granted
  14. US 7488806

    Human antibodies to human delta like ligand 4

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 10, 2009 · Expires Feb 5, 2029

    granted
  15. US 7482002

    Method of administering and using VEGF inhibitors for the treatment of prostate cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 27, 2009 · Expires Jan 22, 2029

    granted
  16. US 7479274

    Method of administering and using VEGF inhibitors for the treatment of pancreatic carcinoma

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 20, 2009 · Expires Jan 15, 2029

    granted
  17. US 7479273

    Method of administering and using VEGF inhibitors for the treatment of renal cell cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 20, 2009 · Expires Jan 15, 2029

    granted
  18. US 7479275

    Method of administering and using VEGF inhibitors for the treatment of colorectal cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 20, 2009 · Expires Jan 15, 2029

    granted
  19. US 7479272

    Method of administering and using VEGF inhibitors for the treatment of breast cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 20, 2009 · Expires Jan 15, 2029

    granted
  20. US 7459426

    Methods of using IL-1 antagonists to treat autoinflammatory disease

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 2, 2008 · Expires Nov 27, 2028

    granted
  21. US 7449182

    Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 11, 2008 · Expires Nov 6, 2028

    granted
  22. US 7417134

    IL-1 receptor based cytokine traps and method of using

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 26, 2008 · Expires Aug 21, 2028

    granted
  23. US 7410781

    IL-4/IL-13 specific polypeptides and therapeutic uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 12, 2008 · Expires Aug 7, 2028

    granted
  24. US 7399612

    VEGF-binding fusion proteins and nucleic acids encoding the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 15, 2008 · Expires Jul 10, 2028

    granted